HistoIndex to Present Latest Findings on AI-based Analysis using Stain-free Digital Pathology with 12 Accepted Abstracts at AASLD The Liver Meeting® 2024
SINGAPORE, Nov. 9, 2024 /PRNewswire/ -- HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present its latest research findings and advancements in AI-based analysis at the 75th The Liver Meeting® (TLM) 2024, hosted by the American Association for the Study of Liver Diseases (AASLD). The conference, which brings together leading scientists, clinicians, and industry...
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity of Saudi Arabia's prominent family business group in the healthcare sector, the Fakeeh Family. The two parties will establish joint ventures in Saudi...
Illumina signs MoU with PHASE to Advance Oncology Testing in the Greater Bay Area and Contribute to the ”Healthy China”
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Illumina Hong Kong LIMITED (Illumina), a global leader in DNA sequencing and array-based technologies, and PHASE Scientific International Limited (PHASE), a Hong Kong-based biotech company with operations in the U.S. and the Greater Bay Area (GBA), signed a three-year Memorandum of Understanding (MoU) on 7 November...
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced groundbreaking research findings demonstrating the potential of its AI to predict...
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024. The post revealed compelling data from the studies...
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
HANOI, Vietnam, Nov. 8, 2024 /PRNewswire/ -- DND International Eye Hospital is the first facility in Vietnam to implement SMILE Pro technology, an advanced FDA-approved eye refractive surgery method. It is also an ideal destination for international tourists seeking to combine travel with refractive eye surgery. Health tourism is rapidly gaining popularity in Asia, and Eye Refractive Surgery in...
Samsung Biologics earns ISO certifications in recognition of business excellence
The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDMO partner INCHEON, South Korea , Nov. 8, 2024 /PRNewswire/ -- Samsung Biologics (KRX:...
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company...
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the submission of an Investigational New Drug (IND) application to the Centre for...
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers Infinitopes' proprietary vector delivery system reliably triggers durable T-cell protection, which halted or delayed tumour progression in industry standard preclinical mouse models, without checkpoint inhibitor co-treatment ...
